Neuro-Sys is both a CRO and a drug discovery company focused on neurodegenerative diseases.
Check our new poster: Pathological role of amyloid peptide in neuromuscular disease, glutamate and glucose involvement.
Alzheimer’s Association International Conference
2016, July 24-27
Check out our booth and poster:
"Mode of action study of NSP01-E, a potential treatment for Alzheimer’s disease, in protection against amyloid β peptide (Aβ) injury."
As a CRO, the Neuro-Sys’ NS-SERVICES department provides the pharmaceutical and biotech industry with efficient and highly skilled preclinical modeling services. With a strong expertize and cutting-edge laboratory equipment, Neuro-Sys develops and uses specific preclinical models of CNS diseases to achieve high-quality efficacy pharmacology and mode of action studies.
We are dedicated to provide high-level technical expertise and preclinical CRO services in a collaborative relationship with our clients, mainly focusing on:
- Alzheimer disease (AD)
- Parkinson disease (PD)
- Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease)
Neuro-Sys also provides efficacy testings for food/dietary supplements and medical nutrition that may have an activity on CNS.
Neuro-Sys set up its proper dedicated drug discovery department NS-PHARMA and laboratory to realize in-house R&D programs with finding new compounds coming from specific medicinal plants as a perspective.
Going forward, the brand new compounds with a proven and demonstrated activity on neurological disorders are put on the market for the pharmacological industry, capable to make all the further development.